Unique ID issued by UMIN | UMIN000038415 |
---|---|
Receipt number | R000043754 |
Scientific Title | Randomized, Parallel Group, Non-intervention-controlled Evaluation of the Efficacy of Exercise Therapy for Patients with CKD |
Date of disclosure of the study information | 2020/12/01 |
Last modified on | 2023/03/26 12:40:36 |
Randomized, Parallel Group, Non-intervention-controlled Evaluation of the Efficacy of Exercise Therapy for Patients
with CKD
Evaluation of the Efficacy of Exercise Therapy for Patients with CKD
Randomized, Parallel Group, Non-intervention-controlled Evaluation of the Efficacy of Exercise Therapy for Patients
with CKD
Evaluation of the Efficacy of Exercise Therapy for Patients with CKD
Japan |
Chronic kidney disease
Nephrology | Rehabilitation medicine |
Others
NO
Examination of the efficacy of exercise therapy for patients with chronic kidney disease
Safety
eGFRCr
Serum concentrations of albumin, creatinine and cystatin C
Urinary concentrations of protein, albumin, B2MG, L-FABP, NGAL, creatinine, and cystatin C, KIM1
PWV
ABI
DEX
Interventional
Parallel
Randomized
Individual
Single blind -investigator(s) and assessor(s) are blinded
No treatment
YES
YES
Institution is considered as adjustment factor in dynamic allocation.
NO
Central registration
2
Treatment
Other |
Treatment group: Aerobic exercise and muscle training will be provided for each patient during the study period (24 weeks).
Control group: Obtain the record of voluntary exercise from each patient.
30 | years-old | <= |
80 | years-old | >= |
Male and Female
CKD patients in whom the cause of renal impairment was examined by renal biopsy
Requirement for steroid therapy
CKD stage IV, V
Uncontrolled hypertension (SBP > 180 mmHg or DBP > 110 mmHg)
Severe anemia (Hb < 7 g/dL)
BMI > 30
Active proliferative diabetic retinopathy
Onset of coronary disease or cerebrovascular disease with in the previous 3 months
Uncontrolled heart failure (NYHA Class III or worse)
Difficulty walking
Other conditions that make patients unsuitable for the study in the investigator's opinion
46
1st name | Naoki |
Middle name | |
Last name | Washida |
International University of Health and Welfare
Nephrology
286-8686
4-3 Kozunomori Narita City
+81-476-20-7701
washida@iuhw.ac.jp
1st name | Takahide |
Middle name | |
Last name | Kimura |
International University of Health and Welfare Atami Hospital
Nephrology
413-0012
13-1 Hgashikaigancho Atami City
+81-557-81-9171
t.kimura@iuhw.ac.jp
International University of Health and Welfare
International University of Health and Welfare
Self funding
International University of Health and Welfare Hospital
International University of Health and Welfare Institutional Review Board
4-3 Kozunomori Narita City
+81-476-20-7703
rinri_md@iuhw.ac.jp
NO
国際医療福祉大学熱海病院(静岡県)、国際医療福祉大学病院(栃木県)
2020 | Year | 12 | Month | 01 | Day |
Unpublished
Completed
2019 | Year | 04 | Month | 01 | Day |
2019 | Year | 04 | Month | 11 | Day |
2020 | Year | 01 | Month | 04 | Day |
2023 | Year | 02 | Month | 12 | Day |
2023 | Year | 02 | Month | 15 | Day |
2023 | Year | 03 | Month | 01 | Day |
2024 | Year | 08 | Month | 01 | Day |
We will start the exercise therapy after three months evaluation of eGFRCr.
We will exclude the patients who will necessitate dosage change of Angiotensin II Receptor Blockers and Angiotensin converting enzyme inhibitors during the examination.
2019 | Year | 10 | Month | 28 | Day |
2023 | Year | 03 | Month | 26 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043754
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |